factual
Cancer drugs cost too much, deliver too little
Although exceptional success stories like Imatinib, Rituximab, and Trastuzumab exist, an empirical and broad look at cancer drugs shows they offer marginal benefits—the median improvement in overall survival across 71 consecutively-approved solid-tumor drugs was 2.1 months—while costing $12-16,000 per month for indefinite, non-curative treatment, producing very poor value.
factualpending
Speaker
Vinay PrasadEvidence Quote
“if you look empirically and broadly at many, many cancer drugs, you will find that they offer very marginal or modest benefits”
Created: 6/13/2026, 12:28:36 AM
Your notes
Loading notes...